Pharma 2010: The Threshold of Innovation
by IBM Corp.
This white paper is part of IBM Business Consulting Services' on-going commitment to forward-looking industry and business points of view, and their aim to help companies and industries transform futures. According to this white paper the pharmaceutical industry will not only make white powders; it will sell a variety of products and therapeutic healthcare packages that include diagnostic tests, drugs and monitoring devices and mechanisms, as well as a wide range of services to support patients. Companies that learn how to make “targeted treatment solutions,” will deliver bigger shareholder returns than they have ever delivered before. This white paper discusses a totally new business model which would reduce the time from target identification to launch from 10-12 years to between three and five years. It could also increase success rates from first human dose to market by a factor of four; and slash costs per drug from an average $800m to as little as $200m. It explains the financial promise of targeted treatment solutions. Companies that fail to respond to the market conditions which are now emerging – and those that are currently most successful may well be those that most resist making the necessary changes. At last, this paper explains what pharmaceutical companies do to pave the way for targeted treatment solutions and what should pharmaceutical companies do to survive in the short term.
| Published: | 2002 |
| Format: | |
| Length: | 12 pages |
| Type: | White paper |
| Language: | English |
.
SPONSORED REPORTS
